Debate over H-1B visas shines spotlight on US tech worker shortages 
3 clinical-grade skincare creams you really shouldn’t buy online 
Oil Prices Rise as Hormuz Reopening Remains Uncertain 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
The pandemic is still disrupting young people’s careers 
Gold Prices Hold Near Seven-Week High as Markets Await U.S. Inflation Data 
Airbus Joins Air India A320 Altitude Drop Probe 
Time to buy local: war fuel price shocks reveal the folly of a long food supply chain 
Glastonbury is as popular than ever, but complaints about the lineup reveal its generational challenge 
The Beauty Beneath the Expressway: A Journey from Self to Service 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
Gold Price Hits Two-Month High as Investors Await US Inflation Data 
Why a ‘rip-off’ degree might be worth the money after all – research study 
Coca-Cola Japan and Kirin Holdings will develop health drinks that contain the live bacteria, lactococcus lactis strain plasma (LC-Plasma), an ingredient patented by Kirin that is used in the company's health drinks.
Kirin claims that the live bacteria boosts immunity in healthy people.
Kirin is the first among companies that make foods and beverages they claim to boost immunity to have been approved by Japan's Consumer Affairs Agency in 2020 to advertise its products as such.
Coca-Cola Japan plans to put LC-Plasma into three of its brands, Georgia, Irohasu, and Minute Maid.
The Consumer Affairs Agency has also given the go-ahead for the drinks to be advertised as having the advantage.
The partnership demonstrates Coca-Cola Japan's intention to improve its position in the health beverage market. According to market research firm Inryo Soken, Coca-Cola has a 26 percent market share in soft drinks but has not advanced significantly in the market for health beverages.
On the other hand, Kirin is increasing sales of its LC-Plasma component and sees health products as its next area of growth. It anticipates that by 2027, sales of health drinks will have increased fivefold from their current level to 50 billion yen.
Taisho Pharmaceutical Holdings, as well as candy manufacturers including Morinaga & Co. and Kanro, have already purchased the component from Kirin.
Although supplying a rival with distinctive ingredients would negate Kirin's advantage, collaborating with Coca-Cola might let it expand its market.
